��������

Sandeep has exhaustive developmental experience in bringing candidates to clinic that span various modalities including gene therapy, ADCs, mAbs, vaccines, oligonucleotides, bi/trispecific, and CART. Prior to joining SalioGen, he worked for 24 years at Pfizer. Recently his team was successful in bringing Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieving emergency use authorization. In his last role as Executive Director, Biotherapeutics Pharmaceutical Sciences, Global Biologics he was responsible for all pre-proof of concept biologics projects, approximately 50 in total, from discovery up to Phase 3 start. Before that, Sandeep established the Protein Pharmaceutical R&D group at Pfizer that included Formulation, Microbiology and Stability functions. Sandeep is active in AAPS and PDA where he has served as Chairman, Arden House Conference on “Parenteral Products: Integrating Science, Innovation and Patient Needs,” Co-Chair, AAPS/FDA/USP workshop on “Future Direction in Aseptic Processing,” and past Chair of Sterile Product Focus group. He is also an adjunct Professor at University of Tennessee. In 2019 Sandeep co-edited ‘Pharmaceutical Dosage Forms: Parenteral Medications” (4th edition). In addition, he has served as Steering Committee Member for the Handbook of Pharmaceutical Excipients. Sandeep has been lead formulator for six launched products and has filed more than 100 INDs/IMPDs (CMC module).